Abstract
Objectives: The purposes of this study were to demonstrate the applicability of pharmacoeconomic principles in the nuclear medicine market and to compare the cost effectiveness of 201TI and 99mTc-sestamibi.
Methods: Cost information was obtained from a South Carolina hospital. Effectiveness data were obtained from the literature.
Results: This research showed that when 201TI was used either one day before or on the day of calibration it was more cost-effective than 99mTc-sestamibi for the detection of coronary artery disease; especially when cardiac scheduling was light. This conclusion held for several varying scenarios. Technetium-99m-sestamibi was more cost-effective than 201TI in the scenarios where patient scheduling was heavy and the 201TI was used three days post-calibration.
Conclusion: Although the generalizability of these results is strictly limited, this research demonstrates the applicability of pharmacoeconomics to radiopharmaceuticals. These results provide some insight into the efficient use of cardiac imaging agents.